Jorge Antonio Esquivel-Valerio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jorge Antonio Esquivel-Valerio has a total of 736 co-authors. Here are the top co-authors by number of shared publications:
- David Vega-Morales
Reumatología y Centro de Infusion, Hospital General de Zona No. 17, Instituto Mexicano del Seguro Social, Monterrey, Mexico
18 shared publications - Dionicio Angel Galarza-Delgado
Rheumatology Department, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México
18 shared publications - Bernardo Antonio Pons‐Estel
Rheumatology, Centro Regional de Enfermedades Autoinmunes y Reumáticas (CREAR), Rosario, Argentina
10 shared publications - Jesus Alberto Cardenas-De la Garza
Rheumatology Department, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México
10 shared publications - Ana Cecilia Arana-Guajardo
Servicio de Reumatología, Instituto de Medicina Interna, Escuela Nacional de Medicina Sistema Tec Salud, Monterrey, Nuevo León, México
9 shared publications - Mario Alberto Garza-Elizondo
Rheumatology, University Hospital and Faculty of Medicine, Autonomous University of Nuevo León (UANL), Monterrey, México
8 shared publications
Latest Publications
- Open Access
- 5 September 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (11) , 7039-7050
Chloroquine and hydroxychloroquine retinopathy in a cohort with rheumatic diseases in Mexico: prevalence, risk factors, and retinopathy patterns
Introduction/objectives To compare chloroquine (CQ) and hydroxychloroquine (HCQ) retinopathy prevalence, risk factors, severity, and patterns in a cohort of Hispanic patients with rheumatic diseases in Mexico. Methods Retrospective, cross-sectional study of patients with rheumatic diseases treated with CQ/HCQ who underwent retinopathy screening (from 2014 to 2019) with macular spectral domain optical coherence tomography and automated visual field tests. The most recent screening report was included to define the presence or absence of retinopathy. Results A total of 571 patients were recruited; 27 were excluded due to missing reports. A total of 544 patients were analyzed, 26% (140/544) used CQ, and 74% (404/544) HCQ. Mean age at treatment initiation was 44.9 ± 15.8 years; 95% were female. Retinopathy prevalence was higher with CQ (19%) than HCQ (2%) (P < 0.001). This was consistent in those using antimalarials < 5 years (CQ: 8.5% vs. HCQ: 1.8%; P < 0.007) and those using antimalarials ≥ 5 years (CQ: 33% vs. HCQ: 2.4%; P < 0.001). CQ patients had more years of use at retinopathy diagnosis than HCQ patients (9.0 ± 4.3 vs. 5.1 ± 3.3, P < 0.023). Parafoveal retinopathy pattern was most frequent in patients using CQ (81%) and HCQ (100%), with no isolated perifoveal pattern. Most patients with retinopathy (59%) had a severe grade. In multivariable regression model, CQ was associated with higher odds of retinopathy compared with HCQ (OR, 12.03; 95% CI 4.41–35.74; P < 0.001). Observed independent risk factors for retinopathy were older age at treatment initiation (OR, 1.04; 95% CI 1.00–1.08; P = 0.029) and years of antimalarial use (OR, 1.18; 95% CI 1.09–1.28; P < 0.001). Conclusion CQ poses a higher risk of antimalarial retinopathy than HCQ. Older age at treatment initiation and duration of use were independent risk factors. Parafoveal was the most frequent retinopathy pattern. Key Points • Antimalarial retinopathy prevalence is significantly higher with chloroquine (19%) than with hydroxychloroquine (2%). • Chloroquine use is associated with significantly higher odds of retinopathy compared with hydroxychloroquine (OR, 12.03; 95% CI 4.41–35.74; P < 0.001). • An older age at treatment initiation (OR, 1.04; 95% CI 1.00–1.08; P = 0.029) and years of antimalarial use (OR, 1.18; 95% CI 1.09–1.28; P < 0.001) are independent risk factors for chloroquine/hydroxychloroquine retinopathy. • The most frequently observed antimalarial retinopathy pattern in this cohort of rheumatic patients in Mexico was the parafoveal (85%), with no cases of perifoveal pattern.
- 5 September 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (11) , 7039-7050
Open AccessChloroquine and hydroxychloroquine retinopathy in a cohort with rheumatic diseases in Mexico: prevalence, risk factors, and retinopathy patterns
Introduction/objectives To compare chloroquine (CQ) and hydroxychloroquine (HCQ) retinopathy prevalence, risk factors, severity, and patterns in a cohort of Hispanic patients with rheumatic diseases in Mexico. Methods Retrospective, cross-sectional study of patients with rheumatic diseases treated with CQ/HCQ who underwent retinopathy screening (from 2014 to 2019) with macular spectral domain optical coherence tomography and automated visual field tests. The most recent screening report was included to define the presence or absence of retinopathy. Results A total of 571 patients were recruited; 27 were excluded due to missing reports. A total of 544 patients were analyzed, 26% (140/544) used CQ, and 74% (404/544) HCQ. Mean age at treatment initiation was 44.9 ± 15.8 years; 95% were female. Retinopathy prevalence was higher with CQ (19%) than HCQ (2%) (P < 0.001). This was consistent in those using antimalarials < 5 years (CQ: 8.5% vs. HCQ: 1.8%; P < 0.007) and those using antimalarials ≥ 5 years (CQ: 33% vs. HCQ: 2.4%; P < 0.001). CQ patients had more years of use at retinopathy diagnosis than HCQ patients (9.0 ± 4.3 vs. 5.1 ± 3.3, P < 0.023). Parafoveal retinopathy pattern was most frequent in patients using CQ (81%) and HCQ (100%), with no isolated perifoveal pattern. Most patients with retinopathy (59%) had a severe grade. In multivariable regression model, CQ was associated with higher odds of retinopathy compared with HCQ (OR, 12.03; 95% CI 4.41–35.74; P < 0.001). Observed independent risk factors for retinopathy were older age at treatment initiation (OR, 1.04; 95% CI 1.00–1.08; P = 0.029) and years of antimalarial use (OR, 1.18; 95% CI 1.09–1.28; P < 0.001). Conclusion CQ poses a higher risk of antimalarial retinopathy than HCQ. Older age at treatment initiation and duration of use were independent risk factors. Parafoveal was the most frequent retinopathy pattern. Key Points • Antimalarial retinopathy prevalence is significantly higher with chloroquine (19%) than with hydroxychloroquine (2%). • Chloroquine use is associated with significantly higher odds of retinopathy compared with hydroxychloroquine (OR, 12.03; 95% CI 4.41–35.74; P < 0.001). • An older age at treatment initiation (OR, 1.04; 95% CI 1.00–1.08; P = 0.029) and years of antimalarial use (OR, 1.18; 95% CI 1.09–1.28; P < 0.001) are independent risk factors for chloroquine/hydroxychloroquine retinopathy. • The most frequently observed antimalarial retinopathy pattern in this cohort of rheumatic patients in Mexico was the parafoveal (85%), with no cases of perifoveal pattern.
- 23 May 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (6) , 105
Body image and sexual function in women with systemic lupus erythematosus: a cross-sectional study
Systemic lupus erythematosus (SLE) is a unique experience for each patient, affecting physical, psychological, and social aspects. Furthermore, body image can be deteriorated. Although both dissatisfaction with body image and sexual dysfunction have been reported in SLE, their relationship remains unclear and has not been previously studied in a Mexican population. Our study aims to determine if body image is correlated with sexual function in women with SLE. A cross-sectional study was conducted in the rheumatology service including adult women aged 18 years or older who met the 2019 EULAR/ACR classification criteria for SLE. Participants completed the Body Esteem Scale (BES), Female Sexual Function Index (FSFI), Rosenberg Self-Esteem Scale (RSES) and Short Form-36 Health Survey (SF-36). All patients provided informed consent. Data from 68 women were analyzed. The mean age was 37.3 ± 13.4 years. Sexual dysfunction was prevalent in 57.4% (n = 39/68) of the participants. While no significant association was found between global body image (BES) and sexual function (r = 0.14, p = 0.24), the sexual attractiveness subdomain was significantly lower in women with dysfunction (3.22 vs. 3.66, p = 0.0125). In the multivariable logistic regression analysis, the primary independent predictors of sexual dysfunction were partner status (OR 0.12; 95% CI 0.02–0.49, p = 0.001), age (OR 1.09; 95% CI 1.02–1.17, p = 0.012), and self-esteem (OR 0.75; 95% CI 0.58–0.92, p = 0.018). Our findings may serve to improve treatment for patients with sexual dysfunction and SLE by offering therapies aimed at enhancing their self-esteem.
- 23 May 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (6) , 105
Body image and sexual function in women with systemic lupus erythematosus: a cross-sectional study
Systemic lupus erythematosus (SLE) is a unique experience for each patient, affecting physical, psychological, and social aspects. Furthermore, body image can be deteriorated. Although both dissatisfaction with body image and sexual dysfunction have been reported in SLE, their relationship remains unclear and has not been previously studied in a Mexican population. Our study aims to determine if body image is correlated with sexual function in women with SLE. A cross-sectional study was conducted in the rheumatology service including adult women aged 18 years or older who met the 2019 EULAR/ACR classification criteria for SLE. Participants completed the Body Esteem Scale (BES), Female Sexual Function Index (FSFI), Rosenberg Self-Esteem Scale (RSES) and Short Form-36 Health Survey (SF-36). All patients provided informed consent. Data from 68 women were analyzed. The mean age was 37.3 ± 13.4 years. Sexual dysfunction was prevalent in 57.4% (n = 39/68) of the participants. While no significant association was found between global body image (BES) and sexual function (r = 0.14, p = 0.24), the sexual attractiveness subdomain was significantly lower in women with dysfunction (3.22 vs. 3.66, p = 0.0125). In the multivariable logistic regression analysis, the primary independent predictors of sexual dysfunction were partner status (OR 0.12; 95% CI 0.02–0.49, p = 0.001), age (OR 1.09; 95% CI 1.02–1.17, p = 0.012), and self-esteem (OR 0.75; 95% CI 0.58–0.92, p = 0.018). Our findings may serve to improve treatment for patients with sexual dysfunction and SLE by offering therapies aimed at enhancing their self-esteem.
- 28 April 2026
- Published by SAGE Publications in Lupus
- Vol. 35 (8) , 818-830
Treatment patterns and outcomes of first lupus nephritis episode over 25 years in two Latin American cohorts
Objectives: To compare the treatments used for the first episode of lupus nephritis (LN) in two Latin American cohorts (historical and contemporary) over a 25-year period, and their associations with clinical outcomes. Methods: Patients with biopsy-confirmed first LN episode were classified as non-proliferative (class V) or proliferative (classes III/IV). Sociodemographic, clinical, and treatment variables were described. Propensity score matching was used to examine the associations with four outcomes: mortality, damage accrual (SDI), hospitalization, and end-stage renal disease (ESRD). Results: A total of 532 SLE patients were included: 362 from GLADEL 1.0 (historical cohort) and 170 from GLADEL 2.0. (contemporary). Compared to GLADEL 1.0, patients in GLADEL 2.0 received lower doses of oral glucocorticoids (GC), more frequently GC pulses and antimalarials but less frequently cyclophosphamide. An increase in the use of mycophenolate mofetil and other immunosuppressants was also observed. In the logistic regression models, SDI was associated with baseline SDI and GC pulses, whereas belonging to the GLADEL 2.0 was a protective factor. Mortality was associated with Mestizo ethnicity and partial health coverage; antimalarial was identified as a protective factor. Hospitalizations were associated with baseline SLEDAI and SDI, follow-up time, and lower educational level. Belonging to the GLADEL 2.0 cohort was protective against the occurrence of ESRD. Conclusions: Patients in the contemporary cohort benefited from advances in treatment strategies, with less cumulative damage and progression to ESRD, although mortality remained unchanged. These improvements likely reflect the increased use of newer therapies, more targeted approaches, in line with current treatment guidelines, and better access to specialized care.
- 28 April 2026
- Published by SAGE Publications in Lupus
- Vol. 35 (8) , 818-830
Treatment patterns and outcomes of first lupus nephritis episode over 25 years in two Latin American cohorts
Objectives: To compare the treatments used for the first episode of lupus nephritis (LN) in two Latin American cohorts (historical and contemporary) over a 25-year period, and their associations with clinical outcomes. Methods: Patients with biopsy-confirmed first LN episode were classified as non-proliferative (class V) or proliferative (classes III/IV). Sociodemographic, clinical, and treatment variables were described. Propensity score matching was used to examine the associations with four outcomes: mortality, damage accrual (SDI), hospitalization, and end-stage renal disease (ESRD). Results: A total of 532 SLE patients were included: 362 from GLADEL 1.0 (historical cohort) and 170 from GLADEL 2.0. (contemporary). Compared to GLADEL 1.0, patients in GLADEL 2.0 received lower doses of oral glucocorticoids (GC), more frequently GC pulses and antimalarials but less frequently cyclophosphamide. An increase in the use of mycophenolate mofetil and other immunosuppressants was also observed. In the logistic regression models, SDI was associated with baseline SDI and GC pulses, whereas belonging to the GLADEL 2.0 was a protective factor. Mortality was associated with Mestizo ethnicity and partial health coverage; antimalarial was identified as a protective factor. Hospitalizations were associated with baseline SLEDAI and SDI, follow-up time, and lower educational level. Belonging to the GLADEL 2.0 cohort was protective against the occurrence of ESRD. Conclusions: Patients in the contemporary cohort benefited from advances in treatment strategies, with less cumulative damage and progression to ESRD, although mortality remained unchanged. These improvements likely reflect the increased use of newer therapies, more targeted approaches, in line with current treatment guidelines, and better access to specialized care.
- Open Access
- 10 April 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (1) , e001881
Demographic and clinical characteristics of patients with systemic lupus erythematosus across five registries: the LupusNet federated data network
Objective: This study describes baseline demographics, clinical characteristics and treatments of patients diagnosed with systemic lupus erythematosus (SLE) at the time of registration in the registries of the Lupus Federated Data Network (LupusNet). Methods: Data were collected from five SLE registries in four global regions: APLC (Asia Pacific), FORWARD (North America), RELESSER (Europe), GLADEL 2.0 and Almenara (Latin America). LupusNet uses a federated data network approach and a privacy-by-design method, where only aggregated results are shared. Demographics, disease activity (based on Physician Global Assessment (PGA) and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores), accumulated damage (Systemic Lupus International Collaborating Clinics Damage Index) and treatment use data were mapped and harmonised using the Observational Medical Outcomes Partnership Common Data Model V.5.4. Results: A total of 10 370 patients were included in the analysis; of those, 3908 patients were in Asia Pacific, 3066 in North America, 1806 in Europe and 1590 in Latin America. The majority of patients were female (91%); the median (IQR) duration from SLE diagnosis to registry entry ranged from 5 (1–12) to 12 (6–19) years. Heterogeneity in disease activity was observed across registries based on mean (SD) SLEDAI-2K total (3.0 (4.1)−7.0 (7.4)) and PGA (0.4 (0.5)−1.2 (1.0)) scores. Across registries, SLE features most common were related to serologic activity (low complement and increased DNA binding (19%–47%)); other common clinical features included proteinuria and arthritis (4%–37%). Cataracts (4%–9%) were the most common characteristic related to accumulated damage. Glucocorticoids, antimalarials and immunosuppressants were the most commonly used treatments, with variations in their proportions observed across registries. Conclusions: These findings demonstrate significant heterogeneity in clinical characteristics and treatment patterns across the registries in LupusNet. By recognising regional differences, findings from LupusNet may help guide treatment approaches in SLE and optimise patient outcomes.
- 10 April 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (1) , e001881
Open AccessDemographic and clinical characteristics of patients with systemic lupus erythematosus across five registries: the LupusNet federated data network
Objective: This study describes baseline demographics, clinical characteristics and treatments of patients diagnosed with systemic lupus erythematosus (SLE) at the time of registration in the registries of the Lupus Federated Data Network (LupusNet). Methods: Data were collected from five SLE registries in four global regions: APLC (Asia Pacific), FORWARD (North America), RELESSER (Europe), GLADEL 2.0 and Almenara (Latin America). LupusNet uses a federated data network approach and a privacy-by-design method, where only aggregated results are shared. Demographics, disease activity (based on Physician Global Assessment (PGA) and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores), accumulated damage (Systemic Lupus International Collaborating Clinics Damage Index) and treatment use data were mapped and harmonised using the Observational Medical Outcomes Partnership Common Data Model V.5.4. Results: A total of 10 370 patients were included in the analysis; of those, 3908 patients were in Asia Pacific, 3066 in North America, 1806 in Europe and 1590 in Latin America. The majority of patients were female (91%); the median (IQR) duration from SLE diagnosis to registry entry ranged from 5 (1–12) to 12 (6–19) years. Heterogeneity in disease activity was observed across registries based on mean (SD) SLEDAI-2K total (3.0 (4.1)−7.0 (7.4)) and PGA (0.4 (0.5)−1.2 (1.0)) scores. Across registries, SLE features most common were related to serologic activity (low complement and increased DNA binding (19%–47%)); other common clinical features included proteinuria and arthritis (4%–37%). Cataracts (4%–9%) were the most common characteristic related to accumulated damage. Glucocorticoids, antimalarials and immunosuppressants were the most commonly used treatments, with variations in their proportions observed across registries. Conclusions: These findings demonstrate significant heterogeneity in clinical characteristics and treatment patterns across the registries in LupusNet. By recognising regional differences, findings from LupusNet may help guide treatment approaches in SLE and optimise patient outcomes.
- Open Access
- 1 January 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (1) , e001878
Baseline characteristics of patients with SLE with and without lupus nephritis from the Latin American multiethnic GLADEL 2.0 cohort
Objective: To describe baseline characteristics of a multinational, multiethnic Latin American cohort of SLE patients with and without lupus nephritis (LN) from Latin American Group for the Study of Lupus (GLADEL) 2.0. Methods: GLADEL 2.0 is an observational prevalent and incident cohort. Adult patients (≥18 years) with SLE who fulfilled the 1982/1997 American College of Rheumatology (ACR) and/or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria from 43 centres in 10 Latin American countries were categorised into four groups: (1) without LN, (2) prevalent inactive LN, (3) prevalent active LN and (4) incident LN. Baseline demographics, clinical manifestations, treatments, disease activity and damage were recorded. A cross-sectional analysis and logistic regression was conducted to identify factors associated with LN and cumulative damage (SLICC/ACR Damage Index (SDI)). Results: Among 1083 patients, 89.6% were female, median age at diagnosis was 27 years, median disease duration was 66.2 months and 65.0% were Mestizo. Patients with LN (n=653) were younger and had shorter disease duration than patients without LN. LN was negatively associated with older age at diagnosis (OR, 0.98) and discoid rash (OR, 0.53) and positively associated with male gender (OR, 1.91), Mestizo ethnicity (OR, 1.46), comorbidities (OR, 3.2), thrombocytopenia (OR, 3.44), anti–double-stranded DNA (anti-dsDNA) positivity (OR, 3.23) and low complement (OR, 1.54). SDI ≥1 was associated with older age at diagnosis, longer disease duration, cumulative prednisone dose and cyclophosphamide use. Conclusions: Male sex, Mestizo ethnicity, comorbidities, thrombocytopenia, anti-dsDNA positivity and low complement levels were associated with LN occurrence. Cumulative damage was associated with older age at diagnosis, longer disease duration, higher cumulative dose of prednisone and the use of cyclophosphamide. Trial registration number: NCT04534647 .
- 1 January 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (1) , e001878
Open AccessBaseline characteristics of patients with SLE with and without lupus nephritis from the Latin American multiethnic GLADEL 2.0 cohort
Objective: To describe baseline characteristics of a multinational, multiethnic Latin American cohort of SLE patients with and without lupus nephritis (LN) from Latin American Group for the Study of Lupus (GLADEL) 2.0. Methods: GLADEL 2.0 is an observational prevalent and incident cohort. Adult patients (≥18 years) with SLE who fulfilled the 1982/1997 American College of Rheumatology (ACR) and/or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria from 43 centres in 10 Latin American countries were categorised into four groups: (1) without LN, (2) prevalent inactive LN, (3) prevalent active LN and (4) incident LN. Baseline demographics, clinical manifestations, treatments, disease activity and damage were recorded. A cross-sectional analysis and logistic regression was conducted to identify factors associated with LN and cumulative damage (SLICC/ACR Damage Index (SDI)). Results: Among 1083 patients, 89.6% were female, median age at diagnosis was 27 years, median disease duration was 66.2 months and 65.0% were Mestizo. Patients with LN (n=653) were younger and had shorter disease duration than patients without LN. LN was negatively associated with older age at diagnosis (OR, 0.98) and discoid rash (OR, 0.53) and positively associated with male gender (OR, 1.91), Mestizo ethnicity (OR, 1.46), comorbidities (OR, 3.2), thrombocytopenia (OR, 3.44), anti–double-stranded DNA (anti-dsDNA) positivity (OR, 3.23) and low complement (OR, 1.54). SDI ≥1 was associated with older age at diagnosis, longer disease duration, cumulative prednisone dose and cyclophosphamide use. Conclusions: Male sex, Mestizo ethnicity, comorbidities, thrombocytopenia, anti-dsDNA positivity and low complement levels were associated with LN occurrence. Cumulative damage was associated with older age at diagnosis, longer disease duration, higher cumulative dose of prednisone and the use of cyclophosphamide. Trial registration number: NCT04534647 .
- 6 June 2024
- Published by SAGE Publications in Lupus
- Vol. 33 (9) , 979-985
Impact of intimate partner violence on quality of life and disease activity in women with systemic lupus erythematosus
Objective: Stress and trauma are psychosocial factors with an impact on the course of systemic lupus erythematosus (SLE). The influence of violence on SLE has not been entirely explored, even though women (including patients with rheumatic diseases) are a vulnerable population to any form of violence. This study aims to assess the prevalence and impact of intimate partner violence (IPV) on health-related quality of life in women with SLE. Methods: An observational, cross-sectional, and analytical study was conducted at a rheumatology clinic of a university hospital from September 2022 and September 2023. We evaluated the presence of IPV in 85 women with SLE with the Hurt, Insulted, Threatened with Harm and Screamed at (HITS) questionnaire and the Index of Spouse Abuse (ISA), and quality of life with LupusQoL. Results: The prevalence by HITS score of past-year IPV was 24.4% and of lifetime IPV was 36.5%. Past-year non-physical violence was present in 17.1% of patients by ISA, and 27.1% were victims in their lifetime. While in physical violence, 7.3% were victims in the previous year and 21.2% in their lifetime. The total quality of life and the emotional domain by LupusQoL were diminished in victims of past-year IPV, compared to those who weren’t exposed ( p = .018 and p = .036, respectively). Past-year HITS score correlated with the Physician Global Assessment (PGA) (rho = 0.301, p = .006), while lifetime HITS score correlated with PGA (rho = 0.329, p = .002) and SLEDAI-2K (rho = 0.277, p = .010). Conclusion: We found that one in four women suffered IPV in the previous year, and those who were exposed had diminished quality of life. Also, the severity of the abuse correlated with disease activity. Our findings emphasize the importance of comprehensive care for patients with SLE.
- 6 June 2024
- Published by SAGE Publications in Lupus
- Vol. 33 (9) , 979-985
Impact of intimate partner violence on quality of life and disease activity in women with systemic lupus erythematosus
Objective: Stress and trauma are psychosocial factors with an impact on the course of systemic lupus erythematosus (SLE). The influence of violence on SLE has not been entirely explored, even though women (including patients with rheumatic diseases) are a vulnerable population to any form of violence. This study aims to assess the prevalence and impact of intimate partner violence (IPV) on health-related quality of life in women with SLE. Methods: An observational, cross-sectional, and analytical study was conducted at a rheumatology clinic of a university hospital from September 2022 and September 2023. We evaluated the presence of IPV in 85 women with SLE with the Hurt, Insulted, Threatened with Harm and Screamed at (HITS) questionnaire and the Index of Spouse Abuse (ISA), and quality of life with LupusQoL. Results: The prevalence by HITS score of past-year IPV was 24.4% and of lifetime IPV was 36.5%. Past-year non-physical violence was present in 17.1% of patients by ISA, and 27.1% were victims in their lifetime. While in physical violence, 7.3% were victims in the previous year and 21.2% in their lifetime. The total quality of life and the emotional domain by LupusQoL were diminished in victims of past-year IPV, compared to those who weren’t exposed ( p = .018 and p = .036, respectively). Past-year HITS score correlated with the Physician Global Assessment (PGA) (rho = 0.301, p = .006), while lifetime HITS score correlated with PGA (rho = 0.329, p = .002) and SLEDAI-2K (rho = 0.277, p = .010). Conclusion: We found that one in four women suffered IPV in the previous year, and those who were exposed had diminished quality of life. Also, the severity of the abuse correlated with disease activity. Our findings emphasize the importance of comprehensive care for patients with SLE.
- 28 November 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (5) , 677-678
Vasculitis that did not read the books
- 28 November 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (5) , 677-678
Vasculitis that did not read the books
- 23 August 2023
- Published by Springer Nature in Rheumatology International
- Vol. 44 (5) , 831-837
Quality indicators and satisfaction with care in patients with systemic lupus erythematosus
Grading the quality of care in patients with systemic lupus erythematosus and determining its relationship with care satisfaction may recognize gaps that could lead to better clinical practice. Eighteen quality indicators (QIs) were recently developed and validated for patients with SLE based on the 2019 EULAR management recommendations. Few studies have analyzed the relationship between quality of care and care satisfaction in patients with lupus. This was a cross-sectional study. We included patients at least 18 years old who met the EULAR/ACR 2019 classification criteria for SLE. We interviewed patients and retrieved data from medical records to assess their compliance with a set of 18 EULAR-based QIs. We calculated each QI fulfillment as the proportion of fulfilled QI divided by the number of eligible patients for each indicator. Care satisfaction was evaluated with the satisfaction domain of LupusPRO version 1.7. Spearman correlation coefficient was used to determine the relationship between quality of care and care satisfaction. Seventy patients with a median age of 33 (IQR 23–48) were included, 90% were women. Overall adherence was 62.29%. The median care satisfaction was 100. Global adherence to the 18-QIs and the care satisfaction score revealed no correlation (r = 0.064, p = 0.599). Higher QI fulfillment was found in the group with remission versus the moderate-high activity group (p = 0.008). In our study, SLE patients in remission had higher fulfillment of quality indicators. We found no correlation between the quality of care and satisfaction with care.
- 23 August 2023
- Published by Springer Nature in Rheumatology International
- Vol. 44 (5) , 831-837
Quality indicators and satisfaction with care in patients with systemic lupus erythematosus
Grading the quality of care in patients with systemic lupus erythematosus and determining its relationship with care satisfaction may recognize gaps that could lead to better clinical practice. Eighteen quality indicators (QIs) were recently developed and validated for patients with SLE based on the 2019 EULAR management recommendations. Few studies have analyzed the relationship between quality of care and care satisfaction in patients with lupus. This was a cross-sectional study. We included patients at least 18 years old who met the EULAR/ACR 2019 classification criteria for SLE. We interviewed patients and retrieved data from medical records to assess their compliance with a set of 18 EULAR-based QIs. We calculated each QI fulfillment as the proportion of fulfilled QI divided by the number of eligible patients for each indicator. Care satisfaction was evaluated with the satisfaction domain of LupusPRO version 1.7. Spearman correlation coefficient was used to determine the relationship between quality of care and care satisfaction. Seventy patients with a median age of 33 (IQR 23–48) were included, 90% were women. Overall adherence was 62.29%. The median care satisfaction was 100. Global adherence to the 18-QIs and the care satisfaction score revealed no correlation (r = 0.064, p = 0.599). Higher QI fulfillment was found in the group with remission versus the moderate-high activity group (p = 0.008). In our study, SLE patients in remission had higher fulfillment of quality indicators. We found no correlation between the quality of care and satisfaction with care.
- Open Access
- 2 May 2023
- Published by Springer Nature in Rheumatology International
- Vol. 43 (7) , 1253-1264
The COVID-19 epidemic curve and vaccine acceptance among patients with rheumatic diseases: an ecological study
The attitudes toward emerging COVID-19 vaccines have been of great interest worldwide, especially among vulnerable populations such as patients with rheumatic and musculoskeletal diseases (RMDs). The aim of this study was to analyze the relationship between the nationwide number of COVID-19 cases and deaths, and vaccine acceptance or hesitancy of patients with RMDs from four patient care centers in Mexico. Furthermore, we explored differences in acceptance according to specific diagnoses: rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). This ecological study was a secondary analysis of a cross-sectional study using a validated questionnaire to measure vaccine acceptance. We generated a global Likert scale to evaluate overall attitudes toward the COVID-19 vaccine. We analyzed data from 1336 patients from March to September 2021: 85.13% (1169) were women, with a mean age of 47.87 (SD 14.14) years. The most frequent diagnoses were RA (42.85%, 559) and SLE (27.08%, 393). 635(47.52%) patients were unvaccinated, 253(18.93%) had one dose and 478(35.77%) had two doses. Of all participating patients, 94% were accepting toward the COVID-19 vaccine. Vaccine acceptance remained consistently high throughout the study. However, differences in vaccine acceptance are identified when comparing diagnoses. The peak of the national epidemic curve coincided with an increase in hesitancy among patients with RA. Contrastingly, patients with SLE became more accepting as the epidemic curve peaked. Mexican patients show high acceptance of the COVID-19 vaccine, influenced in part by a patient’s specific diagnosis. Furthermore, vaccine acceptance increased mirroring the curve of COVID-19 cases and deaths in the country. This should be taken into consideration when updating recommendations for clinical practice.
- 2 May 2023
- Published by Springer Nature in Rheumatology International
- Vol. 43 (7) , 1253-1264
Open AccessThe COVID-19 epidemic curve and vaccine acceptance among patients with rheumatic diseases: an ecological study
The attitudes toward emerging COVID-19 vaccines have been of great interest worldwide, especially among vulnerable populations such as patients with rheumatic and musculoskeletal diseases (RMDs). The aim of this study was to analyze the relationship between the nationwide number of COVID-19 cases and deaths, and vaccine acceptance or hesitancy of patients with RMDs from four patient care centers in Mexico. Furthermore, we explored differences in acceptance according to specific diagnoses: rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). This ecological study was a secondary analysis of a cross-sectional study using a validated questionnaire to measure vaccine acceptance. We generated a global Likert scale to evaluate overall attitudes toward the COVID-19 vaccine. We analyzed data from 1336 patients from March to September 2021: 85.13% (1169) were women, with a mean age of 47.87 (SD 14.14) years. The most frequent diagnoses were RA (42.85%, 559) and SLE (27.08%, 393). 635(47.52%) patients were unvaccinated, 253(18.93%) had one dose and 478(35.77%) had two doses. Of all participating patients, 94% were accepting toward the COVID-19 vaccine. Vaccine acceptance remained consistently high throughout the study. However, differences in vaccine acceptance are identified when comparing diagnoses. The peak of the national epidemic curve coincided with an increase in hesitancy among patients with RA. Contrastingly, patients with SLE became more accepting as the epidemic curve peaked. Mexican patients show high acceptance of the COVID-19 vaccine, influenced in part by a patient’s specific diagnosis. Furthermore, vaccine acceptance increased mirroring the curve of COVID-19 cases and deaths in the country. This should be taken into consideration when updating recommendations for clinical practice.
- 25 November 2022
- Published by Wiley in International Journal of Immunogenetics
- Vol. 50 (1) , 19-23
Rheumatoid arthritis‐associated antibodies in healthy first‐degree relatives of RA patients
Rheumatoid arthritis (RA) affects approximately 1.5% of the population worldwide and 0.5-3.3% of the Mexican population. The presence of rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) and anti-carbamylated protein (anti-CarP) antibodies has been described in populations at risk of RA development, such as first-degree relatives (FDR). Anti-CarP antibodies are present in RA patients (44%), FDR of RA patients (18%) and healthy controls (4.7%). Anti-CarP antibodies have not been described in FDR of the Mexican population. The objective of this study was to determine the prevalence of Rheumatoid Factors (RF) isotypes, ACPA and anti-CarP antibodies isotypes in FDR of RA patients. An observational, cross-sectional study, in an FDR of RA cohort, was performed. We measured IgA, IgG and IgM isotypes of RF, ACPA and anti-CarP antibodies. A total of 144 FDRs from 99 RA patients were enrolled. The prevalence of anti-CarP antibodies was 2.8% for IgA, 4.2% for IgG, whereas IgM was not detected. The serologic association was for RF/ACPA 4.48%, RF/anti-CarP 2.7%, FR 64.5%, ACPA 1.3%, ACPA/anti-CarP 0.69%, anti-CarP 3.4%, and no RF/ACPA/anti-CarP was observed. We found a low prevalence of anti-CarP antibodies in our cohort of FDR of RA patients, but the prevalence of ACPA and RF were higher than other cohorts previously reported.
- 25 November 2022
- Published by Wiley in International Journal of Immunogenetics
- Vol. 50 (1) , 19-23
Rheumatoid arthritis‐associated antibodies in healthy first‐degree relatives of RA patients
Rheumatoid arthritis (RA) affects approximately 1.5% of the population worldwide and 0.5-3.3% of the Mexican population. The presence of rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) and anti-carbamylated protein (anti-CarP) antibodies has been described in populations at risk of RA development, such as first-degree relatives (FDR). Anti-CarP antibodies are present in RA patients (44%), FDR of RA patients (18%) and healthy controls (4.7%). Anti-CarP antibodies have not been described in FDR of the Mexican population. The objective of this study was to determine the prevalence of Rheumatoid Factors (RF) isotypes, ACPA and anti-CarP antibodies isotypes in FDR of RA patients. An observational, cross-sectional study, in an FDR of RA cohort, was performed. We measured IgA, IgG and IgM isotypes of RF, ACPA and anti-CarP antibodies. A total of 144 FDRs from 99 RA patients were enrolled. The prevalence of anti-CarP antibodies was 2.8% for IgA, 4.2% for IgG, whereas IgM was not detected. The serologic association was for RF/ACPA 4.48%, RF/anti-CarP 2.7%, FR 64.5%, ACPA 1.3%, ACPA/anti-CarP 0.69%, anti-CarP 3.4%, and no RF/ACPA/anti-CarP was observed. We found a low prevalence of anti-CarP antibodies in our cohort of FDR of RA patients, but the prevalence of ACPA and RF were higher than other cohorts previously reported.